Iloprost Hameln

Iloprost, the active ingredient in Iloprost Hameln, is a prostacyclin analog presented as a solution for injection for intravenous use. It treats pulmonary arterial hypertension and digital ulcers associated with systemic sclerosis.\n\nGNH India supplies Iloprost Hameln as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Iloprost acts on the prostacyclin pathway to manage severe vascular disorders.\n\nPulmonary arterial hypertension: improves exercise capacity and reduces pulmonary vascular resistance.\nDigital ulcers associated with systemic sclerosis: promotes ulcer healing and reduces new ulcer formation.\nSevere Raynaud's phenomenon: alleviates vasospasm and improves peripheral blood flow.

Common Side Effects:\n- Headache\n- Flushing or warmth sensation\n- Nausea or vomiting\n- Jaw or tooth pain\n- Hypotension during infusion\n- Infusion‑site pain or erythema\n\nSerious or Rare Side Effects:\n- Severe hypotension or shock\n- Significant bleeding or hemorrhage\n- Pulmonary edema or fluid overload\n- Thrombocytopenia or platelet dysfunction\n- Cardiac arrhythmias\n- Anaphylactic or severe allergic reactions

Iloprost should be used with caution in specific clinical situations.\n\nRenal impairment: monitor renal function and adjust therapy as needed.\nHepatic impairment: use with caution and observe liver enzymes.\nBleeding risk: avoid concomitant anticoagulants unless medically required.\nPregnancy: safety not established; weigh benefits against potential risks.\nHypotension: monitor blood pressure before and during infusion.\nStore at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Iloprost may interact with several drug classes, requiring careful management.\n\nMajor Interactions (Avoid):\n- Potent vasodilators (e.g., nitroglycerin): risk of severe hypotension.\n- Anticoagulants (e.g., warfarin, heparin): increased bleeding tendency.\n- Epoprostenol or other prostacyclin analogues: additive vasodilatory effect.\n\nModerate Interactions (Monitor Closely):\n- Calcium‑channel blockers: may enhance hypotensive response.\n- Non‑steroidal anti‑inflammatory drugs (NSAIDs): potential impact on platelet function.\n- Selective serotonin reuptake inhibitors (SSRIs): possible alteration of platelet aggregation.